Allogene Therapeutics advances early LBCL intervention with integrated ALPHA3 trial

Allogene Therapeutics advances early LBCL intervention with integrated ALPHA3 trial
Allogene launches ALPHA3 LBCL trial

Allogene Therapeutics is integrating investigational minimal residual disease (MRD) testing technology with its off-the-shelf CAR T cell therapy in the ALPHA3 trial targeting large B-cell lymphoma (LBCL).

The company aims to intervene earlier in the treatment pathway for LBCL, where one in three patients experience cancer recurrence after first-line therapy. This trial is designed to potentially improve cure rates among these patients.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.